Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise
Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...
Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff
Incyte said on Monday it will buy Vega ​Therapeutics, a wholly owned subsidiary of privately held Star Therapeutics, in a ...
MedCity News
Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug
Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing ...
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Edgewise Therapeutics (EWTX) stays a Buy after its $2.65B Servier deal funds EDG-7500 for HCM with key Q2 2026 data. Read ...
BioPharma Dive
Incyte to buy blood disorder drug in possibly $2B deal
Incyte, a drugmaker with a heavy focus on blood diseases and cancers, plans to take control of an experimental medicine that could help control bleeding in a variety of disorders. Vega Therapeutics, a ...